Anatomic, morphologic and genetic heterogeneity of prostate cancer: Implications for clinical practice

Expert Review of Anticancer Therapy

Volumn 12, Issue 11, 2012, Pages 1371-1374

  Cheng, Liang ^a   MacLennan, Gregory T ^b   Lopez Beltran, Antonio ^c   Montironi, Rodolfo ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

carcinogenesis; field effect; focal therapy; Gleason grading; multifocal; precursor lesions; prostate; prostatic intraepithelial neoplasia; staging and classification; tumor heterogeneity

Indexed keywords

ABLATION THERAPY; CANCER GRADING; CLINICAL PRACTICE; CLONAL EVOLUTION; GENETIC HETEROGENEITY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; OUTCOME ASSESSMENT; PATHOLOGICAL ANATOMY; PREDICTION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; TREATMENT PLANNING; TUMOR BIOPSY; TUMOR VOLUME;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASMS, MULTIPLE PRIMARY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84871272835     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.127     Document Type: Review

References (23)

1. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO. Anatomic distribution and pathologic characterization of smallvolume prostate cancer (<0.5 ml) in wholemount prostatectomy specimens. Mod. Pathol. 18(8), 1022-1026 (2005).
2. Cheng L, Poulos CK, Pan CX et al. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J. Urol. 174(3), 898-902 (2005).
3. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100(11), 2362-2366 (2004).
4. Eichelberger LE, Cheng L. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. Cancer 100(12), 2573-2576 (2004).
5. Cheng L, Song SY, Pretlow TG et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J. Natl Cancer Inst. 90(3), 233-237 (1998).
6. Bostwick DG, Cheng L. Precursors of prostate cancer. Histopathology 60(1), 4-27 (2012).
7. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am. J. Surg. Path. 12, 897-906 (1988).
8. Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod. Pathol. 22(7), 866-871 (2009).
9. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum. Pathol. 41(6), 781-793 (2010).
10. Liu W, Laitinen S, Khan S et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15(5), 559-565 (2009).
11. Masterson TA, Cheng L, Mehan RM, Koch MO. Tumor focality does not predict biochemical recurrence after radical prostatectomy in men with clinically localized prostate cancer. J. Urol. 186(2), 506-510 (2011).
12. Masterson TA, Cheng L, Koch MO. Pathological characterization of unifocal prostate cancers in whole-mount radical prostatectomy specimens. BJU Int. 107(10), 1587-1591 (2011).
13. Eichelberger LE, Koch MO, Daggy JK, Ulbright TM, Eble JN, Cheng L. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am. J. Clin. Pathol. 120(3), 386-391 (2003).
14. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM. Staging of prostate cancer. Histopathology 60(1), 87-117 (2012).
15. Eichelberger LE, Koch MO, Eble JN, Ulbright TM, Juliar BE, Cheng L. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod. Pathol. 18(7), 886-890 (2005).
16. Cheng L, Davidson DD, Lin H, Koch MO. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer 110(9), 1967-1972 (2007).
17. Cheng L, Koch MO, Juliar BE et al. The combined percentage of Gleason patterns and 5 is the best predictor of cancer progression after radical prostatectomy. J. Clin. Oncol. 23(13), 2911-2917 (2005).
18. Hattab EM, Koch MO, Eble JN, Lin H, Cheng L. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. J. Urol. 175(5), 1695-1699; discussion 1699 (2006).
19. Lopez-Beltran A, Cheng L, Blanca A, Montironi R. Cell proliferation and apoptosis in prostate needle biopsies with adenocarcinoma Gleason score 6 or 7. Anal. Quant. Cytol. Histol. 34(2), 61-65 (2012).
20. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 281(15), 1395-1400 (1999).
21. de la Rosette J, Ahmed H, Barentsz J et al. Focal therapy in prostate cancer-report from a consensus panel. J. Endourol. 24, 775-780 (2010).
22. Koch MO, Gardner T, Cheng L et al. Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J. Urol. 178(6), 2366-2370; discussion 2370 (2007).
23. Vlaeminck-Guillem V, Devonec M, Colombel M, Rodriguez-Lafrasse C, Decaussin-Petrucci M, Ruffion A. Urinary PCA3 score predicts prostate cancer multifocality. J. Urol. 185(4), 1234-1239 (2011).